DELAWARE
|
|
25-1741849
|
(State or other jurisdiction of incorporation or organization)
|
|
(I.R.S. Employer Identification No.)
|
o Large accelerated filer
|
o Accelerated filer
|
o Non-accelerated filer
|
x smaller reporting company
|
PART I
|
||
|
|
|
ITEM 1.
|
BUSINESS
|
4
|
ITEM 1A.
|
RISK FACTORS
|
13
|
ITEM 1B.
|
UNRESOLVED STAFF COMMENTS
|
18
|
ITEM 2.
|
PROPERTIES
|
18
|
ITEM 3.
|
LEGAL PROCEEDINGS
|
18
|
ITEM 4.
|
MINE SAFETY DISCLOSURES
|
18
|
|
|
|
PART II
|
||
|
|
|
ITEM 5.
|
MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
|
19
|
ITEM 6.
|
SELECTED FINANCIAL DATA
|
21
|
ITEM 7.
|
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
|
21
|
ITEM 7A.
|
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
|
26
|
ITEM 8.
|
FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
|
26
|
ITEM 9.
|
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
|
26
|
ITEM 9A.
|
CONTROLS AND PROCEDURES
|
26
|
ITEM 9B.
|
OTHER INFORMATION
|
27
|
|
|
|
PART III
|
||
|
|
|
ITEM 10.
|
DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERANCE
|
28
|
ITEM 11.
|
EXECUTIVE COMPENSATION
|
30
|
ITEM 12.
|
33
|
|
ITEM 13.
|
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
|
34
|
ITEM 14.
|
PRINCIPAL ACCOUNTING FEES AND SERVICES
|
34
|
|
|
|
PART IV
|
||
|
|
|
ITEM 15.
|
36
|
|
|
|
|
62
|
NAME AND ADDRESS OF BENEFICIAL OWNER
|
|
TITLE
OF CLASS
|
|
AMOUNT AND
NATURE OF
BENEFICIAL
OWNERSHIP
|
|
|
PERCENT
OF CLASS
|
|
Ulrich Burkhard (1) Director
|
|
Common
|
|
--
|
|
|
0
|
%
|
|
|
|
|
|
|
|
|
|
Dr. Thomas Staehelin (1) Director
|
|
Common
|
|
12,479,907
|
|
|
4.23
|
%
|
|
|
|
|
|
|
|
|
|
Dr. Sylvain Fleury (1) Chief Scientific Officer
|
|
Common
|
|
6,500,000
|
(2)
|
|
2.20
|
%
|
|
|
|
|
|
|
|
|
|
Ernest M. Stern (1) Director
|
|
Common
|
|
1,500,000
|
(3)
|
|
0.51
|
%
|
|
|
|
|
|
|
|
|
|
Ronald Kempers (1) CEO, CFO and Director
|
|
Common
|
|
100,000
|
|
|
0.03
|
%
|
|
|
|
|
|
|
|
|
|
All current executive officers and directors as a group (5 persons)
|
|
Common
|
|
20,579,907
|
|
|
6.97
|
%
|
|
|
|
|
|
|
|
|
|
Round Enterprises Ltd. (1)
|
|
Common
|
|
141,006,552
|
(4)
|
|
47.75
|
%
|
(1) | Address is Mymetics Corporation, Biopole, Route de la Corniche 4, CH-1066 Epalinges (Switzerland). |
(2) | Of which 500,000 were issued for services, 1,000,000 were acquired through conversion of unpaid salary and expenses and 5,000,000 were acquired as a bonus. |
(3) | 500,000 were issued for services rendered. |
(4) | As stated in the Form 13-D filed by Round Enterprises Ltd. all its shares are held through Anglo Irish Bank, SA, as nominee which, as a fiduciary, cannot take any action without the prior consent of Round Enterprises Ltd. |
|
(a)
|
(1)
|
Index to Financial Statements
|
|
|
|
|
|
|
|
Report of Independent Registered Public Accounting Firm
|
|
|
|
|
|
|
|
Consolidated Balance Sheets
|
|
|
|
|
|
|
|
Consolidated Statements of Operations and Comprehensive Loss
|
|
|
|
|
|
|
|
Consolidated Statements of Changes in Shareholders' Equity (Deficit)
|
|
|
|
|
|
|
|
Consolidated Statements of Cash Flows
|
|
|
|
|
|
|
|
Notes to Consolidated Financial Statements
|
|
|
|
|
|
(a)
|
(2)
|
ALL OTHER SCHEDULES HAVE BEEN OMITTED BECAUSE THEY ARE NOT APPLICABLE OR THE REQUIRED INFORMATION IS SHOWN IN THE FINANCIAL STATEMENTS OR NOTES THERETO.
|
|
|
|
|
|
|
(3)
|
List of Exhibits
|
|
|
|
|
|
2.1
|
|
Share Exchange Agreement dated December 13, 2001 between the Company and the stockholders of Mymetics S.A. listed on the signature page thereto (1)
|
|
|
|
|
|
2.2
|
|
Share Exchange Agreement dated December 13, 2001 between the Company and the stockholders of Mymetics S.A. listed on the signature page thereto (1)
|
|
|
|
|
|
2.3
|
|
Purchase Agreement dated October 17, 1998 between the Company and the majority stockholders of Nazca Holdings Ltd. (2)
|
|
|
|
|
|
2.4
|
|
Amendment to the Purchase Agreement dated October 17, 1998 between the Company and the majority stockholders of Nazca Holdings Ltd. (3)
|
|
|
|
|
|
2.5
|
|
Revised Purchase Agreement dated July 28, 1999 between the Company and the majority stockholders of Nazca Holdings Ltd. (4)
|
|
|
|
|
|
2.6
|
|
Share Exchange Agreement dated July 30, 2002 between the Company and the stockholders of Mymetics S.A. listed on the signature page thereto (5)
|
|
|
|
|
|
3 (i)
|
|
Articles of Incorporation of the Company (as amended through May 10, 2002) (6)
|
|
|
|
|
|
3 (ii)
|
|
Bylaws (7)
|
|
|
|
|
|
4.1
|
|
Form of Specimen Stock Certificate (8)
|
|
|
|
|
|
4.2
|
|
Form of letter regarding Warrant (8)
|
|
|
|
|
|
4.3
|
|
Form of Share Exchange Agreement (8)
|
|
|
|
|
|
9.1
|
|
Voting and Exchange Trust Agreement dated March 19, 2001, among the Company, 6543 Luxembourg S.A. and MFC Merchant Bank S.A. (8)
|
|
|
|
|
|
10.1
|
|
Services Agreement dated May 31, 2001, between the Company and MFC Merchant Bank, S.A.(7)
|
|
|
|
|
|
10.2
|
|
Employment Agreement dated May 3, 2001, between Pierre-Francois Serres and the Company (7)
|
|
|
|
|
|
10.3
|
|
Indemnification Agreement dated March 19, 2001, between the Company and MFC Bancorp Ltd. (7)
|
|
|
|
|
|
10.4
|
|
Agreement dated for reference May 15, 2000, between the Company and Maarten Reidel (7)
|
|
10.5
|
|
Preferred Stock Redemption and Conversion Agreement dated for reference December 21, 2000, between the Company and Sutton Park International Ltd. (10)
|
|
|
|
|
|
10.6
|
|
Preferred Stock Conversion Agreement dated for reference December 21, 2000, between the Company and Med Net International Ltd. (11)
|
|
|
|
|
|
10.7
|
|
Preferred Stock Conversion Agreement dated December 21, 2000, between the Company and Dresden Papier GmbH (11)
|
|
|
|
|
|
10.8
|
|
Assignment Agreement dated December 29, 2000, among the Company, Mymetics S.A. and MFC Merchant Bank S.A. (1)
|
|
|
|
|
|
10.9
|
|
Credit Facility Agreement dated July 27, 2000, between MFC Merchant Bank, S.A. and the Company (1)
|
|
|
|
|
|
10.10
|
|
Amended Credit Facility Agreement dated for reference August 13, 2001, between MFC Merchant Bank, S.A. and the Company (16)
|
|
|
|
|
|
10.11
|
|
Second Amended Credit Facility Agreement dated for reference February 27, 2002, between MFC Merchant Bank, S.A. and the Company (16)
|
|
|
|
|
|
10.12
|
|
Amended and Restated Credit Facility Agreement dated for reference February 28, 2003, among MFC Merchant Bank, S.A., MFC Bancorp Ltd., and the Company (16)
|
|
|
|
|
|
10.13
|
|
Guarantee dated for reference February 28, 2003, by MFC Bancorp Ltd. to MFC Merchant Bank S.A. (16)
|
|
|
|
|
|
10.14
|
|
Shareholder Agreement dated March 19, 2001, among the Company, the Holders of Class B Exchangeable Preferential Non-Voting Shares of 6543 Luxembourg S.A. signatory thereto and6543 Luxembourg S.A.(8)
|
|
|
|
|
|
10.15
|
|
Support Agreement dated March 19, 2001, between the Company and 6543 Luxembourg S.A. (8)
|
|
|
|
|
|
10.16
|
|
1995 Qualified Incentive Stock Option Plan (12)
|
|
|
|
|
|
10.17
|
|
Amended 1994 Stock Option Plan (13)
|
|
|
|
|
|
10.18
|
|
2001 ICHOR Company Stock Option Plan (7)
|
|
|
|
|
|
10.19
|
|
Employment Agreement dated March 18, 2002, between the Company and Peter P. McCann (14)
|
|
|
|
|
|
10.20
|
|
Consulting Agreement dated August 31, 2001, between the Company and Michael K. Allio (8)
|
|
|
|
|
|
10.21
|
|
Amendment to Consulting Agreement dated August 21, 2002, between the Company and Michael K. Allio (16)
|
|
|
|
|
|
10.22
|
|
Employment Agreement dated March 18, 2002, between the Company and Dr. Joseph D. Mosca (15)
|
|
|
|
|
|
10.23
|
|
Separation Agreement and Release dated January 31, 2003,between the Company and Peter P. McCann (16)
|
|
|
|
|
|
10.24
|
|
Director and Non-Employee Stock Option Agreement dated July 19, 2001, between the Company and Robert Demers (8)
|
|
|
|
|
|
10.25
|
|
Director and Non-Employee Stock Option Agreement dated July 19, 2001, between the Company and Michael K. Allio (8)
|
|
|
|
|
|
10.26
|
|
Director and Non-Employee Stock Option Agreement dated July 19, 2001, between the Company and John M. Musacchio (8)
|
|
|
|
|
|
10.27
|
|
Director and Non-Employee Stock Option Agreement dated July 19, 2001, between the Company and Patrice Pactol (8)
|
|
|
|
|
|
10.28
|
|
Director and Non-Employee Stock Option Agreement dated July 19, 2001, between the Company and Pierre-Francois Serres (8)
|
|
|
|
|
|
10.29
|
|
Director and Non-Employee Stock Option Agreement dated July 23, 2002, between the Company and Pierre-Francois Serres (16)
|
|
10.30
|
|
Director and Non-Employee Stock Option Agreement dated July 23 2002, between the Company and Patrice Pactol (16)
|
|
|
|
|
|
10.31
|
|
Director and Non-Employee Stock Option Agreement dated July 23,2002, between the Company and Robert Demers (16)
|
|
|
|
|
|
10.32
|
|
Director and Non-Employee Stock Option Agreement dated July 23, 2002, between the Company and John M. Musacchio (16)
|
|
|
|
|
|
10.33
|
|
Director and Non-Employee Stock Option Agreement dated July 23, 2002, between the Company and Michael K. Allio (16)
|
|
|
|
|
|
10.34
|
|
Director and Non-Employee Stock Option Agreement dated August 21, 2002, between the Company and Michael K. Allio (16)
|
|
|
|
|
|
10.35
|
|
Director and Non-Employee Stock Option Agreement dated June 20, 2002, between the Company and Peter P. McCann (16)
|
|
|
|
|
|
10.36
|
|
Director and Non-Employee Stock Option Agreement dated July 23, 2002, between the Company and Peter P. McCann (16)
|
|
|
|
|
|
10.37
|
|
Director and Non-Employee Stock Option Agreement dated February 6, 2003, between the Company and Peter P. McCann (16)
|
|
|
|
|
|
10.38
|
|
Patent Pledge Agreement dated November __, 2002 among Mymetics S.A., Mymetics Deutschland GmbH, the Company and MFC Merchant Bank S.A. (16)
|
|
|
|
|
|
10.39
|
|
Third Amendment to the Credit Facility Agreement dated for Reference December 31, 2006, between MFC Merchant Bank, S.A. and the Company (17)
|
|
|
|
|
|
10.40
|
|
Fourth Amendment to the Credit Facility Agreement dated for Reference February 16, 2005, between MFC Merchant Bank, S.A. and the Company (17)
|
|
|
|
|
|
10.41
|
|
Consulting Agreement dated for reference January 1, 2004, between the Centre Hospitalier Universitaire Vaudois (CHUV), the Company and Dr. Sylvain Fleury, Ph.D. (18)
|
|
|
|
|
|
10.42
|
|
Consulting Agreement dated for reference January 1, 2004, between the Company and Professor Marc Girard, DVM, D.Sc. (18)
|
|
|
|
|
|
10.43
|
|
Cooperation and Option Agreement dated March 10, 2005, between the Company and Pevion A.G. (18)
|
|
|
|
|
|
10.44
|
|
Consulting Agreement dated March 23, 2005, between the Company and Northern Light International. (18)
|
|
|
|
|
|
10.45
|
|
Sixth Amended Credit Facility Agreement dated for reference December 31, 2005, between MFC Merchant Bank, S.A. and the Company (19)
|
|
|
|
|
|
10.46
|
|
Employment Agreement dated July 1, 2006, between the Company and Dr. Sylvain Fleury (20)
|
|
|
|
|
|
10.47
|
|
Employment Agreement dated July 1, 2006, between the Company and Christian Rochet (20)
|
|
|
|
|
|
10.48
|
|
Employment Agreement dated July 1, 2006, between the Company and Ernst Luebke (20)
|
|
|
|
|
|
10.49
|
|
License Agreement dated March 1, 2007, between the Company and Pevion Biotech Ltd. (21)
|
|
|
|
|
|
10.50
|
|
Settlement Agreement dated March 19, 2007 between the Company and MFC Merchant Bank S.A. (22)
|
|
|
|
|
|
10.51
|
|
Co-ownership Agreement dated January 8, 2008 between the Company, INSERM and Pevion Biotech Ltd. (23)
|
|
|
|
|
|
10.52
|
|
Co-ownership Agreement dated January 8, 2008 between the Company and INSERM (23)
|
|
10.53
|
|
Exploitation Agreement dated January 8, 2008 between the Company and INSERM (23)
|
|
|
|
|
|
10.54
|
|
Non-Executive Director Agreement dated 21 January between the Company and Mr. Ernest M Stern.(24)
|
|
|
|
|
|
10.55
|
|
NGIN Material Transfer Agreement dated 11 February 2008 between the Company, Institute Cochin, Universite Paris Descartes and Pevion Biotech.(25)
|
|
|
|
|
|
10.56
|
|
Acquisition & License Agreement dated 19 May 2008 between the Company and Pevion Biotech Ltd. (26)
|
|
|
|
|
|
10.57
|
|
Extension of Convertible Note Maturity Date Agreement dated 22 August 2008 between the Company, Anglo Irish Bank and Round Enterprises Ltd. (27)
|
|
|
|
|
|
10.58
|
|
Gp41 Manufacturing Technology Agreement dated 26 January 2009 between the Company and PX Therapeutics (28)
|
|
|
|
|
|
10.59
|
|
Share Purchase Agreement pursuant to which the Company purchased all issued and outstanding shares of capital stock of Bestewil Holding B.V. (“Bestewil”) from its parent, Norwood Immunology Limited (“NIL”), and all issued and outstanding shares of capital stock of Virosome Biologicals B.V. now held by Bestewil. (29)
|
|
|
|
|
|
10.60
|
|
Resignation of Prof Marc Girard as Head of vaccine development for reasons of personal health. (30)
|
|
|
|
|
|
10.61
|
|
Completion of Share Purchase Agreement pursuant to which Mymetics purchased all issued and outstanding shares of capital stock of Bestewil Holding B.V. and Virosome Biologicals B.V. including Unregistered Sales of Equity Securities, Financial Statements and Exhibits. (31)
|
|
|
|
|
|
10.62
|
|
Completion of Share Purchase Agreement pursuant to which Mymetics purchased all issued and outstanding shares of capital stock of Bestewil Holding B.V. and Virosome Biologicals B.V. including Statements and Exhibits. (32)
|
|
10.63
|
|
Election of Jacques-Francois Martin as a member of the Board of Directors and Chairman of the Board, resignation of Christian Rochet as President and CEO and agreement of Jacques-Francois Martin to serve as President and CEO. (33)
|
|
|
|
|
|
10.64
|
|
Consulting Agreement dated September 1, 2009, between the Company and Mr. Christian Rochet.
|
|
|
|
|
|
10.65
|
|
Resignation of Ernest Luebke as Chief Finance Officer and Board member. (37)
|
|
|
|
|
|
10.66
|
|
Press release on partial funding by the National Institutes of Health of a new preclinical trial to test the effectiveness of a candidate HIV vaccine in a nonhuman primate model. (38)
|
|
10.67
|
|
Amendment of Exploitation Agreement dated January 8, 2008 with INSERM-TRANSFERT. (43)
|
|
|
|
|
|
10.67
|
|
Amendment of License and Cooperation Agreements for Intranasal Delivery of APRECS based Vaccines and Virosomes between Mymetics B.V. and Abbott Biologicals B.V (44)
|
|
|
|
|
|
10.68
|
|
Election of Martine Reindle to the Board of Directors. (45)
|
|
|
|
|
|
10.68
|
|
Resignation of Jacques-François Martin as President and CEO. (46)
|
|
|
|
|
|
10.69
|
|
Election of Dr. Christopher S. Henney, Ulrich Burkhard and Grant Pickering to the Board of Directors. Resignation of Jacques-François Martin, Martine Reindle, Christian Rochet and Sylvain Fleury from the Board of Directors. (47)
|
|
|
|
|
|
10.70
|
|
Second Amended and Restated Executive Employment Agreement of Dr. Sylvain Fleury. (49)
|
|
|
|
|
|
10.71
|
|
Amendment of convertible secured notes issued to Round Enterprises Ltd., Eardley Holding A.G. and Anglo Irish Bank. (50)
|
|
|
|
|
|
10.72
|
|
Election of Ronald Kempers as President and Chief Executive Officer. , Departure of Dr. Christopher S. Henney and Grant Pickering from the Board of Directors. (51)
|
|
|
|
|
|
11.1
|
|
Statement Regarding Calculation of Per Share Earnings.
|
|
|
|
|
|
14.1
|
|
Code of Ethics.
|
|
21.1
|
|
List of Subsidiaries
|
|
|
|
|
|
24.1
|
|
Powers of Attorney (included on the signature page hereto)
|
|
|
|
|
|
|
Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14 of the Securities Exchange Act of 1934
|
|
|
|
|
|
|
|
Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14 of the Securities Exchange Act of 1934
|
|
|
|
|
|
|
|
Section 1350 Certification of Chief Executive Officer and Chief Financial Officer
|
|
|
|
|
|
|
101.INS
|
|
Instance Document
|
|
|
|
|
|
101.SCH
|
|
XBRL Taxonomy Extension Schema Document
|
|
|
|
|
|
101.CAL
|
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
|
|
|
|
101.DEF
|
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
|
|
|
|
101.LAB
|
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
|
|
|
|
101.PRE
|
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
(1) | Incorporated by reference to the Company's Schedule 14C filed with the Securities and Exchange Commission on April 26, 2001. |
(2) | Incorporated by reference to the Company's report on Form 8-K filed with the Securities and Exchange Commission on October 22, 1998. |
(3) | Incorporated by reference to the Company's report on Form 8-K/A filed with the Securities and Exchange Commission on April 15, 1999. |
(4) | Incorporated by reference to the Company's report on Form 8-K/A filed with the Securities and Exchange Commission on August 13, 1999. |
(5) | Incorporated by reference to the Company's Amendment No. 1 to Form S-1 filed with the Securities and Exchange Commission on August 8, 2002. |
(6) | Incorporated by reference to the Company's report on Form 10-Q for the quarter ended March 31, 2002, filed with the Securities and Exchange Commission on May 15, 2002. |
(7) | Incorporated by reference to the Company's report on Form 10-Q for the quarter ended June 30, 2001, filed with the Securities and Exchange Commission on August 14, 2001. |
(8) | Incorporated by reference to the Company’s Registration Statement on Form S-1, File No. 333-88782, filed with the Securities and Exchange Commission on May 22, 2002. |
(9) | Incorporated by reference to the Company's report on Form 8-K/A filed with the Securities and Exchange Commission on August 9, 2000. |
(10) | Incorporated by reference to Schedule 13D/A filed by MFC Bancorp Ltd. with the Securities and Exchange Commission on dated January 2, 2001. |
(11) | Incorporated by reference to the Company's report on Form 10-K for the fiscal year ended December 31, 2000, filed with the Securities and Exchange Commission on March 14, 2001. |
(12) | Incorporate by reference to the Company's Registration Statement on Form S-8, File No. 333-15831, filed with the Securities and Exchange Commission on November 8, 1996. |
(13) | Incorporated by reference to the Company's Registration Statement on Form S-8, File No. 333-15829, filed with the Securities and Exchange Commission on November 8, 1996. |
(14) | Incorporated by reference to the Company's report on Form 10-K for the fiscal year ended December 31, 2004, and filed with the Securities and Exchange Commission on March 29, 2002. |
(15) | Incorporated by reference to the Company's report on Form 10-Q for the quarter ended March 31, 2002, filed with the Securities and Exchange Commission on May 15, 2002. |
(16) | Incorporated by reference to the Company's report on Form 10-K for the fiscal year ended December 31, 2005, and filed with the Securities and Exchange Commission on March 27, 2003. |
(17) | Incorporated by reference to the Company's report on Form 8-K filed with the Securities and Exchange Commission on February 18, 2005. |
(18) | Incorporated by reference to the Company's report on Form 10-K for the fiscal year ended December 31, 2004, filed with the Securities and Exchange Commission on March 30, 2005. |
(19) | Incorporated by reference to the Company's report on Form 10-K for the fiscal year ended December 31, 2005, filed with the Securities and Exchange Commission on April 17, 2006. |
(20) | Incorporated by reference to the Company's report on Form 10-Q for the period ended June 30, 2006, and filed with the Securities and Exchange Commission on August 21, 2006. |
(21) | Incorporated by reference to the Company's report on Form 10-K for the fiscal year ended December 31, 2006, filed with the Securities and Exchange Commission on April 17, 2007. |
(22) | Incorporated by reference to the Company's report on Form 8-K filed with the Securities and Exchange Commission on March 21, 2007. |
(23) | Incorporated by reference to the Company's report on Form 8-K filed with the Securities and Exchange Commission on January 14, 2008. |
(24) | Incorporated by reference to the Company's report on Form 8-K filed with the Securities and Exchange Commission on January 25, 2008. |
(25) | Incorporated by reference to the Company's report on Form 8-K filed with the Securities and Exchange Commission on February 19, 2008. |
(26) | Incorporated by reference to the Company's report on Form 8-K filed with the Securities and Exchange Commission on May 19, 2008. |
(27) | Incorporated by reference to the Company's report on Form 8-K filed with the Securities and Exchange Commission on June 30, 2008. |
(28) | Incorporated by reference to the Company's report on Form 8-K filed with the Securities and Exchange Commission on January 30, 2009. |
(29) | Incorporated by reference to the Company's report on Form 8-K filed with the Securities and Exchange Commission on March 5, 2009. |
(30) | Incorporated by reference to the Company's report on Form 8-K filed with the Securities and Exchange Commission on March 9, 2009. |
(31) | Incorporated by reference to the Company's report on Form 8-K filed with the Securities and Exchange Commission on June 16, 2009. |
(32) | Incorporated by reference to the Company's report on Form 8-K/A filed with the Securities and Exchange Commission on June 22, 2009. |
(33) | Incorporated by reference to the Company's report on Form 8-K filed with the Securities and Exchange Commission on June 23, 2009. |
(34) | Incorporated by reference to the Company's Statement on Form 4, filed with the Securities and Exchange Commission on July 28, 2009. |
(35) | Incorporated by reference to the Company's Statement on Form 3 filed with the Securities and Exchange Commission on July 14, 2010. |
(36) | Incorporated by reference to the Company's Statement on Form 3 filed with the Securities and Exchange Commission on August 9, 2010. |
(37) | Incorporated by reference to the Company's report on Form 8-K filed with the Securities and Exchange Commission on August 10, 2010. |
(38) | Incorporated by reference to the Company's report on Form 8-K filed with the Securities and Exchange Commission on September 13, 2010. |
(39) | Incorporated by reference to the Company's Statement on Form 4 filed with the Securities and Exchange Commission on December 2, 2010. |
(40) | Incorporated by reference to the Company's Statement on Form 3 filed with the Securities and Exchange Commission on December 20, 2010. |
(41) | Incorporated by reference to the Company's report on Form 8-K filed with the Securities and Exchange Commission on March 7, 2011. |
(42) | Incorporated by reference to the Company's report on Form 8-K filed with the Securities and Exchange Commission on March 16, 2011. |
(43) | Incorporated by reference to the Company's report on Form 8-K filed with the Securities and Exchange Commission on August 12, 2011. |
(44) | Incorporated by reference to the Company's report on Form 8-K filed with the Securities and Exchange Commission on October 4, 2011. |
(45) | Incorporated by reference to the Company's report on Form 8-K filed with the Securities and Exchange Commission on October 26, 2011. |
(46) | Incorporated by reference to the Company's report on Form 8-K filed with the Securities and Exchange Commission on February 03, 2012. |
(47) | Incorporated by reference to the Company's report on Form 8-K filed with the Securities and Exchange Commission on March 23, 2012. |
(48) | Incorporated by reference to the Company's Statement on Form 13D filed with the Securities and Exchange Commission on April 05, 2012. |
(49) | Incorporated by reference to the Company's report on Form 8-K filed with the Securities and Exchange Commission on July 02, 2012. |
(50) | Incorporated by reference to the Company's report on Form 8-K filed with the Securities and Exchange Commission on September 21, 2012. |
(51) | Incorporated by reference to the Company's report on Form 8-K filed with the Securities and Exchange Commission on November 26, 2012. |
|
Mymetics Corporation
|
|
|
|
|
|
|
|
By:
|
/s/ Ronald Kempers
|
|
|
|
|
|
|
Name: Ronald Kempers
|
|
|
|
Title: Chief Executive Officer / Chief Financial Officer
|
|
|
|
July 9, 2013
|
|